Company Overview and News
Small-cap stocks continue to put some distance between themselves and their large cap brethren. Though the Dow Jones Industrial Average and the S&P 500 ended Monday’s trading in the red on lingering fears of a trade war, once again the Russell 2000 Small Cap Index mustered a gain most other market indices couldn’t. Indeed, it’s likely that small-cap stocks are outpacing large cap alternatives specifically because they’re better shielded from an international trade war.
TTMI RUN PBH USNA AOBC NVDA GSK OSUR JNJ MRK CDXS INTC
From 5/15/18-6/15/18, Fredrik Arnold dividend "followers" discussed 36 equities and funds in messages and comments. Some comments were bad news, so rogues created a FollowerFavorite/Rogue (FoFa/Ro) list.
CY WDC ORC CYS.PRA CAPL CLNS.PRDCL CJR.B CYS.PRB AGNC ABBV CLNS APLE CLNS.PRJ CLNS.PRI CLNS.PRH CLNS.PRG CLNS.PRE CLNS.PRD DWDP CLNS.PRB CYS ARR CJREF GMLP JNJ SIR ARR.PRB ABBV ARR.PRA
May 15-June 15, Fredrik Arnold "followers" mentioned 37 equities in their comments and suggestions. Some lamented bad news so bad news stocks mixed in with their favorites.
JE GIS CLA CTL ORC ROYT HCLP JE CYS.PRA CAPL CLNS.PRDCL CJR.B CYS.PRB TWO CPTA TWO.PRA JE.PRA TWO.PRB TWO.PRC MO CLNS CLNS.PRJ CLNS.PRI CLNS.PRH CLNS.PRG CLNS.PRE CLNS.PRD CLNS.PRB CYS FRO CJREF GMLP JNJ
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG IRET.PR DUKH GD IRET.PRC TRV IRET.PRB GPT.PRB MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA GPT.PRA INTC TD IBM IRET.PRCL RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
May set a new record with $369 in dividend come, up 33% Y/Y and 109% sequentially.
JD WFCNP TXN BZUN WFC.PRL MOMO WFC.PRJ RDSB NVDA RDSA WFC.PRT WFC.PRR WFC.PRQ AMZN WFC.PRP WFC.PRO WFC.PRN AAPL VNNVF WFC.PRY RYDAF INTC WFC.PRX WFC.PRW BGS MCD WFC.PRV WFC WFC.WS RDS.B RDS.A GILD CBAUF VONOY TGT V JNJ MU RYDBF
Philip Morris has increased its dividend for 10 of the last ten years in a row and presently has a yield of 5.6%, which is well above average.
HD PM GE GEC ADP ADPVV JNJ IR KHC GNE OHI BA MO
General Electric Co. (NYSE: GE) shares lost about 4.5% last week, solidly establishing the industrial giant as the worst performer among the Dow equities for the year to date. So far in 2018 the shares have lost 23.8%.
GE GEC MTSI PG JNJ GNE WMT MMM
In March and April, I wrote a series of articles that examined how far several large-cap service sector stocks might fall during a bear market, and I suggested some alternative investments.
UNP VPU CCL FDX BRK.A SPGI GWW MGA JNJ MG CCL PAYX
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA
In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place.
SOJA SO MTSI AWK TWX GOOG WM TWC WMT BRK.A AMZN T CL JNJ GOOGL MMM
“It took us 50 years to get here. We’re not going to unwind this thing in a few weeks,” Hedgeye Health Policy analyst Emily explains in the clip above.
There is a laundry list of worries that are starting to jump on the plates of investors, not the least of which was confirmed by the Federal Reserve meeting this week, where it became pretty clear we will have a total of four rate increases in 2018 as opposed to three. Toss in the worries over the trade tariffs, which now look like they will be imposed in early July, and there are plenty of reasons to be nervous.
ABT JNJ ABBV LLY ZTS ABT ABBV
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to JNJ / Johnson & Johnson on message board site Silicon Investor.
|JNJ-Super company, Super stock!|
as of ET